Hepatotoxicity Observed in Clinical Trials of Aplaviroc (GW873140)

Aplaviroc (APL) was a new CCR5 antagonist that was investigated in two dose-ranging studies with antiretroviral therapy-naïve, human immunodeficiency virus-infected adults: ASCENT, in which 147 subjects were randomized 2:2:1 to receive zidovudine-lamivudine (ZDV-3TC) plus APL 600 mg twice a day (BID...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Nichols, W. G., Steel, H. M., Bonny, T., Adkison, K., Curtis, L., Millard, J., Kabeya, K., Clumeck, N.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society for Microbiology (ASM) 2008
Assuntos:
Antiviral Agents
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2258506/
https://ncbi.nlm.nih.gov/pubmed/18070967
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.00821-07
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados